{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Pediatrix Medical Group, Inc.
Pediatrix Medical Group Hits Day High with 24.22% Surge in Stock Price
Pediatrix Medical Group, Inc. has shown strong performance, achieving a notable gain and reaching an intraday high. Over the past year, it has significantly outperformed the S&P 500. The company boasts a solid market capitalization, efficient management metrics, and robust financial health, indicating its strong position in the Pharmaceuticals & Biotechnology sector.
Pediatrix Medical Group Hits New 52-Week High of $21.24
Pediatrix Medical Group, Inc. achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market cap of USD 1,476 million, the company boasts impressive financial metrics, including a favorable P/E ratio, solid return on equity, and robust operating cash flow.
Pediatrix Medical Group Achieves Strong Valuation Metrics Amid Impressive Growth Performance
Pediatrix Medical Group, Inc. has recently experienced a valuation adjustment, reflecting a favorable assessment of its financial health. Key indicators include a competitive P/E ratio of 8, strong operational efficiency with a ROCE of 16.57%, and impressive profit growth of 44.5% over the past year.
Is Pediatrix Medical Group, Inc. overvalued or undervalued?
As of October 17, 2025, Pediatrix Medical Group, Inc. is considered very attractive and undervalued, with a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, outperforming peers and the S&P 500 with a year-to-date return of 25.38%.
Pediatrix Medical Group, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Metrics
Pediatrix Medical Group, Inc. has recently adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 8 and a PEG ratio of 0.19. The company has demonstrated resilience with a ROCE of 16.57% and a ROE of 19.10%, outperforming the S&P 500 over the past year.
Is Pediatrix Medical Group, Inc. overvalued or undervalued?
As of October 17, 2025, Pediatrix Medical Group, Inc. is considered very attractive due to its undervalued status, with a P/E ratio of 8 and a year-to-date return of 25.38%, significantly outperforming the S&P 500's 13.30%.
Is Pediatrix Medical Group, Inc. overvalued or undervalued?
As of October 17, 2025, Pediatrix Medical Group, Inc. is considered very attractive in valuation due to its low P/E ratio of 8, strong year-to-date return of 25.38%, and ROE of 19.10%, especially when compared to peers like Hims & Hers Health, Inc. with a P/E of 54.76.
Pediatrix Medical Group Hits New 52-Week High of $18.21
Pediatrix Medical Group, Inc. achieved a new 52-week high of USD 18.21 on October 7, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. With a market cap of USD 1,476 million, the company showcases solid financial metrics, including a P/E ratio of 8.00 and a return on equity of 18.01%.
Is Pediatrix Medical Group, Inc. technically bullish or bearish?
As of August 29, 2025, Pediatrix Medical Group, Inc. shows a bullish trend supported by positive MACD and KST readings, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year.
Is Pediatrix Medical Group, Inc. overvalued or undervalued?
As of August 5, 2025, Pediatrix Medical Group, Inc. is considered a very attractive investment due to its undervalued metrics, including a P/E ratio of 8 and a year-to-date return of 26.45%, despite a longer-term struggle compared to the S&P 500.
Is Pediatrix Medical Group, Inc. overvalued or undervalued?
As of February 20, 2024, Pediatrix Medical Group, Inc. is considered undervalued with a P/E ratio of 8, an EV to EBITDA ratio of 7.17, and strong returns on capital and equity, indicating potential for growth compared to its peers.
Is Pediatrix Medical Group, Inc. technically bullish or bearish?
As of May 23, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators show mild bearishness, resulting in a mixed overall outlook.
Who are in the management team of Pediatrix Medical Group, Inc.?
As of March 2022, the management team of Pediatrix Medical Group, Inc. includes Mr. Guy Sansone (Independent Chairman), Mr. Manuel Kadre (Lead Independent Director), Dr. Roger Medel, Ms. Karey Barker, Dr. Waldemar Carlo, and Mr. Paul Gabos, all serving as directors. They are responsible for the company's strategic direction and governance.
What does Pediatrix Medical Group, Inc. do?
Pediatrix Medical Group, Inc. provides physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care. As of March 2025, it reported net sales of $458 million and a net profit of $21 million, with a market cap of $1.15 billion.
How big is Pediatrix Medical Group, Inc.?
As of Jun 18, Pediatrix Medical Group, Inc. has a market capitalization of 1,152.00 million and reported net sales of 1,976.18 million with a net profit of -82.37 million over the latest four quarters. Shareholder's funds are 764.94 million, and total assets amount to 2,152.70 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
